drugset
drugset / Trial / NCT00060372

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

NCT00060372 ↗

Phase 1 Completed 21 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

Timeline

Start
2003-04
Primary completion
2008-04
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody — Intravenous

Indications

B-cell chronic lymphocytic leukemia Burkitt lymphoma Hodgkins lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative childhood myelodysplastic syndrome choriocarcinoma of ovary choriocarcinoma of testis chronic myeloid leukemia diffuse large B-cell lymphoma female breast carcinoma immature ovarian teratoma large-cell immunoblastic lymphoma mantle cell lymphoma mature ovarian teratoma neuroblastoma ovarian carcinoma ovarian embryonal carcinoma ovarian mixed germ cell neoplasm ovarian monodermal and highly specialized teratoma ovarian yolk sac tumor plasma cell myeloma polyembryoma of the ovary testicular embryonal carcinoma testicular teratoma testicular yolk sac tumor